← Leaderboards
Tomi K Sawyer
Courage Therapeutics, Inc.
$2,164,996
Attributed
$2,164,996
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $862.7K · FY2020–23$1M$750K$500K$250K$0
'20
'21
'22
'23
Funding mix
By agency
NIH$2,164,996 · 3
By mechanism
R42$1,669,553 · 1
R41$495,443 · 2
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Small Business Technology Transfer Research”
- Molly Wasko · University Of Alabama At Birmingham$18,764,568
- Christian Harding · Vaxnewmo, Llc$7,493,429
- Tina Garyantes · Linnaeus Therapeutics, Llc$6,999,960
- Ashkan Vaziri · Biosensics, Llc$5,841,222
- Sarah Emily Snider · Beam Diagnostics, Inc.$5,670,978
- Joseph Cheng · University Of Illinois At Urbana-Champaign$4,985,809
Research focus
Small Business Technology Transfer ResearchDesignReceptorMelanocortin 3 ReceptorAgonistPeptidesPeptide ReceptorPharmaceutical PreparationsIn VivoSyndromeIn VitroEatingObesityNeuronsAnalogBrainAmericanMelanocortin ReceptorMelanocortin 4 ReceptorMetabolic Abnormality AssessmentPathway InteractionsHalf-LifeExhibitsDrug Kinetics
Grant awards (4)
Development of Novel Melanocortin-4 Receptor Peptide Agonists for the Treatment ofMC4R Haploinsufficiency$862,674
R42 · FY2023 · DK · contact PI
Development of Novel Melanocortin-4 Receptor Peptide Agonists for the Treatment ofMC4R Haploinsufficiency$806,879
R42 · FY2022 · DK · contact PI
Development of Melanocortin-3 Receptor Peptide Agonists for the Treatment of Anorexia Nervosa$250,538
R41 · FY2021 · MH · contact PI
Development of Melanocortin-3 Receptor Peptide Antagonists for the Treatment of Obesity and Maintenance of Weight Loss$244,905
R41 · FY2020 · DK · contact PI